Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: 
A case report

Lai,Shiue‑Wei; Huang,Tzu‑Chuan; Chen,Jia‑Hong; Wu,Yi‑Ying; Chang,Ping‑Ying

doi:10.3892/ol.2015.2928

Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report

Authors:
- Shiue‑Wei Lai
- Tzu‑Chuan Huang
- Jia‑Hong Chen
- Yi‑Ying Wu
- Ping‑Ying Chang
View Affiliations

Affiliations: Department of Internal Medicine, Division of Hematology and Oncology, Tri‑Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
Published online on: February 3, 2015 https://doi.org/10.3892/ol.2015.2928
Pages: 1957-1961

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

BCR‑ABL tyrosine‑kinase inhibitors are the first‑line therapy for the majority of patients with chronic myelogenous leukemia (CML). Up to 20% of patients who have imatinib‑treated CML in blast crisis (BC) experience a relapse in the central nervous system (CNS) due to the poor penetration of the drug by the blood‑brain barrier. The present case reports a successful experience of using dasatinib‑based combination therapy to treat a 22‑year‑old female who presented with initial symptoms of intermittent fever and easy bruising under the diagnosis of CML in BC. Although the patient eventually succumbed to profound sepsis, the CNS involvement was treated successfully using dasatinib-based combination therapy (cranial radiation and de-escalated intrathecal chemotherapy). This case demonstrates that dasatinib may be a viable option for those who are not medically fit for or are otherwise unwilling to receive high‑dose chemotherapy. It appears that dose intensity is essential for optimal efficacy and should be maintained at 150 mg daily as far as possible.

View Figures

View References

1	Schiffer CA: BCR-ABl tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 357:258–265. 2007. View Article : Google Scholar : PubMed/NCBI
2	Carella AM, Branford S, Deininger M, et al: What challenges remain in chronic myeloid leukemia research? Haematologica. 98:1168–1172. 2013. View Article : Google Scholar : PubMed/NCBI
3	Pfeifer H, Wassmann B, Hofmann WK, et al: Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res. 9:4674–4681. 2003.PubMed/NCBI
4	Leis JF, Stepan DE, Curtin PT, et al: Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma. 45:695–698. 2004. View Article : Google Scholar : PubMed/NCBI
5	Wolff NC, Richardson JA, Egorin M and Ilaria RL Jr: The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood. 101:5010–5013. 2003. View Article : Google Scholar : PubMed/NCBI
6	Petzer AL, Gunsilius E, Hayes M, et al: Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol. 117:623–625. 2002. View Article : Google Scholar : PubMed/NCBI
7	Bornhauser M, Jenke A, Freiberg-Richter J, et al: CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol. 83:401–402. 2004. View Article : Google Scholar
8	Dai H, Marbach P, Lemaire M, Hayes M and Elmquist WF: Distribution of STI-571 to the brain is limited by p-glycoprotein-mediated efflux. J Pharmacol Exp Ther. 304:1085–1092. 2003. View Article : Google Scholar : PubMed/NCBI
9	Bujassoum S, Rifkind J and Lipton JH: Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma. 45:401–403. 2004. View Article : Google Scholar : PubMed/NCBI
10	Isobe Y, Sugimoto K, Masuda A, Hamano Y and Oshimi K: Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate. Intern Med J. 39:408–411. 2009. View Article : Google Scholar : PubMed/NCBI
11	Hochhaus A, Kantarjian HM, Baccarani M, et al: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109:2303–2309. 2007. View Article : Google Scholar
12	Kantarjian HM, Giles F, Gattermann N, et al: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 110:3540–3546. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 362:2260–2270. 2010. View Article : Google Scholar : PubMed/NCBI
14	Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 362:2251–2259. 2010. View Article : Google Scholar : PubMed/NCBI
15	Porkka K, Koskenvesa P, Lundan T, et al: Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 112:1005–1012. 2008. View Article : Google Scholar : PubMed/NCBI
16	Abdelhalim A, Barcos M, Block AW, et al: Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leuk Lymphoma. 48:1053–1056. 2007. View Article : Google Scholar : PubMed/NCBI
17	Alimena G, Breccia M, Latagliata R, et al: Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations. Leuk Res. 33:e134–e136. 2009. View Article : Google Scholar : PubMed/NCBI
18	Nishimoto M, Nakamae H, Koh KR, et al: Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia. Acta Haematol. 130:111–114. 2013. View Article : Google Scholar : PubMed/NCBI
19	Gutierrez-Aguirre H, Garcia-Rodriguez F, Cantu-Rodriguez O, Gonzalez-Llano O, Jaime-Perez J and Gomez-Almaguer D: Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report. Clin Adv Hematol Oncol. 9:875–878. 2011.
20	Papageorgiou SG, Pappa V, Economopoulou C, et al: Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression. Leuk Res. 34:e254–e256. 2010. View Article : Google Scholar : PubMed/NCBI
21	Frigeri F, Arcamone M, Luciano L, Di Francia R, Pane F and Pinto A: Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia. Blood. 113:5028–5029. 2009. View Article : Google Scholar : PubMed/NCBI
22	Cortes J: Central nervous system involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 15:145–162. 2001. View Article : Google Scholar : PubMed/NCBI
23	O’Hare T, Walters DK, Stoffregen EP, et al: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65:4500–4505. 2005. View Article : Google Scholar
24	Shah NP, Tran C, Lee FY, Chen P, Norris D and Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 305:399–401. 2004. View Article : Google Scholar : PubMed/NCBI
25	McCormack PL and Keam SJ: Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 71:1771–1795. 2011. View Article : Google Scholar : PubMed/NCBI